Skip to content
Menu

Adaptive Biotechnologies Corporation ADPT

Full chart Compare
Set alert

Price alert · ADPT

All alert types
27.90 USD -0.15 (-0.53%)

As ofNov 20, 2026, 1:24 PM EST

27.15 Day range 28.23
12.00 52-week range 32.21
YTD
+71.80%
1 year
+70.96%

5D -1.00 (-3.44%)

2829FriMonTueWedThu28.05
Market cap
4.52B
Revenue (ttm)
298.01M
Profit margin
-23.66%
EPS (ttm)
-0.45
Shares out
161.88M
Forward P/E
-841.58
YTD return
+71.80%
1-year return
+70.96%
50-day average
27.14
200-day average
20.23
Volume
639.83K
Avg volume
2.19M
Open
27.43
Previous close
28.05
Day's range
27.15 – 28.23
52-week range
12.00 – 32.21
Beta
2.15
Analysts
Strong Buy
Price target
32.57 (+16.7%)
Earnings date
Feb 4, 2027

Key statistics

Enterprise value
4.72B
Price / sales
15.24
Price / book
25.71
Revenue growth
-10.70%
Free cash flow
14.43M
Total cash
298.95M
Total debt
408.97M
Return on equity
-36.45%
Short % of float
8.93%

Fundamental scorecard

5 of 25 checks passed on ADPT’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ADPT Revenue — quarterly 83.90M
ADPT Net income — quarterly 2.88M
ADPT EPS — quarterly 0.02

Earnings

ADPT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 4, 2027Dec 30, 2026-0.04———
Nov 4, 2026Sep 30, 2026-0.091080.02+0.11+121.96%
Jul 28, 2026Jun 30, 2026-0.13361-0.25-0.12-87.11%
May 5, 2026Mar 31, 2026-0.16-0.13+0.03+18.75%
Feb 5, 2026Dec 31, 2025-0.19-0.09+0.10+52.63%
Nov 6, 2025Sep 30, 2025-0.180.06+0.24+133.33%

Upgrades / downgrades

ADPT analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026GuggenheimmainBuyBuy
Oct 13, 2026TD CowenmainBuyBuy
Oct 13, 2026Morgan StanleymainEqual-WeightEqual-Weight
Oct 1, 2026GuggenheimmainBuyBuy
Sep 29, 2026Goldman Sachsinit—Buy
Sep 22, 2026BTIGmainBuyBuy

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States

News

Your note

Sign in to keep a note on ADPT — it syncs with the Stock Master app.

Insider holders

ADPT insider holders
InsiderRelationLatest transactionDateShares held
BENZENO SHARONOfficerConversion of Exercise of derivative securityJun 28, 2026221,278
BOBULSKY SUSANOfficerSaleOct 5, 2026389,350
LO FRANCISOfficerConversion of Exercise of derivative securitySep 30, 2026223,367
NEUPERT PETER MDirectorConversion of Exercise of derivative securityAug 16, 2026130,625
OWEN KATEY EINTERZDirectorStock GiftAug 30, 202666,100
PELLINI MICHAEL JDirectorStock Award(Grant)Mar 3, 202569,690

Institution ownership

ADPT institution ownership
Holder% heldSharesValueReported
Viking Global Investors, L.P.18.53%29,993,708841.32MSep 29, 2026
Blackrock Inc.9.45%15,302,445429.23MSep 29, 2026
Vanguard Capital Management LLC3.98%6,436,045180.53MSep 29, 2026
Shaw D.E. & Co., Inc.3.94%6,373,294178.77MSep 29, 2026
Price (T.Rowe) Associates Inc3.52%5,702,859159.97MSep 29, 2026
Vanguard Portfolio Management LLC3.24%5,239,185146.96MSep 29, 2026

Fund ownership

ADPT fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.99%4,834,309135.60MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.55%4,122,023115.62MSep 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF1.17%1,891,30353.05MOct 30, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.08%1,742,85448.89MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund1.04%1,687,24147.33MAug 30, 2026
ALGER FUNDS-Alger Small Cap Focus Fund0.92%1,494,21441.91MJul 30, 2026